Navigation Links
Greffex Inc. Signs Manufacturing Contract with FUJIFILM Diosynth Biotechnologies to Produce Vaccines

Greffex, a leading genetic engineering company, with the world’s first universal vaccine platform delivered through the use of proprietary clean viral vectors, recently announced a key manufacturing agreement with FUJIFILM Diosynth Biotechnologies to produce its vaccine in the United States. Greffex’s platform is the world’s most successful gene therapy delivery vehicle (vector) with broad applications for delivering treatments including vaccines, immune suppression and gene therapy.

"We are delighted to be selected by Greffex as their CDMO (Contract Development & Manufacturing Organization) partner," said Gerry Farrell, chief operating officer, FDB Texas site. "FDB looks forward to our work together to bring these ground-breaking therapies to market to meet the critical need for global vaccines. "

John R. Price, Greffex Co-Chairman of the Board, President and CEO said “Greffex is excited to be working with FUJI Diosynth. This is a major step in our progression; helping to fulfill our vision of becoming an international Bio Pharmaceutical Company Headquartered in Texas creating innovative therapies to protect and heal mankind.”

In 2019, Greffex was awarded an $18.9 million contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. This award will enable Greffex to develop and exploit its GreVac(TM) Plug-And-Play Technology to expedite the production of vaccine candidates for biodefense and emerging infectious diseases to target infectious threats, whether natural or man-made.

Greffex, a leading genetic engineering company founded in 2005, has developed the world’s first universal vaccine platform that delivers unprecedented time-to-market, cost efficiency, efficacy and safety through the use of proprietary clean viral vectors. The company has 14 vaccines in its development portfolio, numerous gene therapies in development including Hemophilia A and Usher Syndrome, and immune tissue engineering aimed at overcoming transplant rejection.

Greffex is headquartered in Houston, Texas with laboratories in Aurora, Colorado.

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology technology :

1. DeepDyve Signs New Partnership Agreement with the Institute of Physics
2. New Vision Test Helps Detect Early Signs of Glaucoma
3. Aluflam Signs Deal To Automate Window & Door Manufacturing
4. EpiVax Signs First Commercial License for Tregitope Technology
5. RepliCels Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems
6. Cousins Properties Signs 125,000 Square Foot Lease with Amgen at Corporate Center in Tampa, FL
7. New Synergy Collection By StemCutis Rejuvenates Skin And Repairs Signs Of Aging
8. Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
9. RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector
10. TRIANNI Signs Licensing Agreement for Transgenic Mouse Platform Use with Janssen
11. THC Signs Definitive Agreement to Purchase Clone Shipper
Post Your Comments:
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , ... sciences and food industries, is pleased to announce that Charles Galea has joined ... Development. , Charles is an accomplished and results-driven sales executive with over 10 ...
(Date:7/10/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join ... Dr. Nissenson serves as an Emeritus Professor of Medicine at the David ...
(Date:7/1/2020)... ... June 29, 2020 , ... The ... purchasing contracts to its membership, recently named BioFit Engineered Products an ... opportunity to purchase ergonomic seating, cafeteria tables, book trucks and carts at discounted ...
(Date:6/28/2020)... HILL, Conn. (PRWEB) , ... June 25, 2020 ... ... company formed to advance photodynamic therapy for treating cancer, today announced the company ... New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to ...
Breaking Biology Technology:
(Date:7/4/2020)... ... July 03, 2020 , ... ... earn outstanding recognition and multiple awards for not only the products and treatments ... SoME® Skincare and Vivace® Microneedle RF. All the brands built by ABM have ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global ... of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of ... located in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical ...
(Date:6/28/2020)... ... ... In an upcoming episode scheduled for the fall of 2020, Advancements with Ted ... local listings for more info. , Today, the majority of testing is performed at ... the country. Results are then available several days later. Now, in an effort to ...
Breaking Biology News(10 mins):